ClinicalTrials.gg
RecruitingNCT07217717FAPI-PROUpdated Oct 19, 2026

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase 3 interventional study of [18F]FAPI-74 PET/CT in Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by SOFIE. Recruiting at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by SOFIE · Phase 3, Interventional, and Diagnostic

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 19, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal adenocarcinoma. Following screening, using a standardized administration protocol and dose, participants will undergo [¹⁸F]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such [¹⁸F]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of [¹⁸F]FAPI-74 PET/CT.

02

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Keywords

  • PDAC
  • FAP
  • FAPI
  • PET
  • Fibroblast Activation Protein
  • Fibroblast Activation Protein Inhibitor
03

In context

Lead sponsor

SOFIE is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults ≥ 18 years.
  • Participants with confirmed PDAC, undergoing staging evaluation for treatment planning.
  • (ECOG) performance status ≤2:
  • Provided signed, written obtained prior to any study-related procedures.
  • Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of [¹⁸F]FAPI-74 administration.
  • For women who are not (two years of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use medically accepted, highly effective methods of (e.g., hormonal implants, combined oral contraceptives, vasectomized partner , during the trial intervention period.

Exclusion criteria

Exclusion Criteria:

  • Unequivocal evidence of at the time of enrollment that would preclude surgery as a treatment option.
  • Known to [¹⁸F]FAPI-74.
  • Administration of another therapeutic or diagnostic product within 30 days prior to [¹⁸F]FAPI-74 administration.
  • Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of [¹⁸F]FAPI-74 administration.
  • Previous cancer diagnosis (except basal cell carcinoma of the skin or in situ carcinoma of the cervix/uterus). Participants treated with curative intent and disease-free for more than 5 years are permitted.
  • Hepatic function: T. bili >1.5X or alk phos, , or AST >5X ULN
  • Renal function: \< 30 mL/min
  • Pregnant or breast feeding (a negative pregnancy test is required in women of )
  • Inability to undergo the PET/CT scanning procedure.
  • Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
  • Sarcoidosis
  • Treatment, including chemotherapy, radiation or surgery for curative intent of PDAC.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Patients with pancreatic ductal adenocarcinoma receiving [18F]FAPI-74

    Drug: [18F]FAPI-74 PET/CT

Interventions

  • Drug[18F]FAPI-74 PET/CT

    Drug page: Fluorine F 18 FAPI-74

    \[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma.

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity for detection of distant metastatic disease (M1) using a composite SOT as reference

    To evaluate the diagnostic performance of \[¹⁸F\]FAPI-74 PET/CT scan in determining the presence or absence of metastatic disease (M1) in patients with pancreatic ductal adenocarcinoma compared with a composite standard of truth (SOT).

    Time frame: Time Frame: From enrollment to the end of treatment after 3 month follow up

Secondary outcomes

  1. Incidence and severity of adverse events using CTCAE v5.

    To assess the safety profile of \[¹⁸F\]FAPI-74 PET/CT.

    Time frame: 24-72 hours post-injection

  2. Cohen's kappa for pairwise evaluation of inter- and intra-reader agreement

    To assess inter-and intra-reader variability in image interpretation of the presence of metastatic disease

    Time frame: From enrollment to the end of treatment after 3 month follow up

  3. Number of participants with treatment-related adverse events as assessed by body temperature changes

    To assess the safety profile of \[¹⁸F\]FAPI-74 PET/CT.

    Time frame: 24-72 hours post-injection

  4. Number of participants with treatment-related adverse events as assessed by blood pressure changes

    To assess the safety profile of \[¹⁸F\]FAPI-74

    Time frame: 24-72 hours post-injection

  5. Number of participants with treatment-related adverse events as assessed by respiration rate

    To assess the safety profile of \[¹⁸F\]FAPI-74

    Time frame: 24-72 hours post-injection

  6. Number of participants with treatment-related adverse events as assessed by pulse rate

    To assess the safety profile of \[¹⁸F\]FAPI-74

    Time frame: 24-72 hours post-injection

07

Study locations

17 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2025
First posted
Oct 16, 2025
StartActual
Dec 11, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Impression Imaging · Coral Springs, United States
  • Mayo Clinic Jacksonville · Jacksonville, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University · Chicago, United States
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    3 sites added
    Show 3 added (3 United States)
    • Impression Imaging · Coral Springs, United States
    • Mayo Clinic Jacksonville · Jacksonville, United States
    • Robert H. Lurie Comprehensive Cancer Center of Northwestern University · Chicago, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07217717
Lead sponsor
SOFIE
Responsible party
Sponsor
First posted
Oct 16, 2025
Start date
Dec 11, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Alex Osipova
Contact
Alex.osipova@sofie.com
1-800-753-5368
Bridget Adams
Contact
bridget.adams@sofie.com
1-800-753-5368
Sherly Mosessian, Ph.D
study director · Sofie Co.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorine F 18 FAPI-74

Start the discussion